Status:

Do Not Prescribe (DNP), Red

Decision Date:

September 2020

Comments

RED⁸: NICE TA643 - for treating ROS1-positive advanced non-small cell lung cancer (Decision date - September 2020) 

DNP: NICE TA1118: (updates and replaces TA644. Terminated appraisal) Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (Decision date February 2026)

Do Not Prescribe (DNP) Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again